MetaCap

Who Owns Denali Therapeutics Stock?

NASDAQ: DNLIHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

18.45+0.25 (+1.37%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Ownership breakdown

Held by institutions
100.11%
Institutional holders
420
  • Institutions 95.4%
  • Insiders 4.6%
  • Public and other 0.0%

Who owns Denali Therapeutics stock?

Institutional investors own about 100.1% of Denali Therapeutics's shares, spread across 420 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 4.59% of DNLI.

The largest institutional holders are T. Rowe Price Investment Management, Inc. (12.24%), Blackrock Inc. (8.94%) and BAILLIE GIFFORD & CO (6.94%). Together, the top 10 institutions control 52.8% of shares outstanding. In their latest filings, 5 of the top 10 institutions increased their DNLI positions and 4 reduced them.

Summary generated from market data by MetaCap's automated system. Methodology

Top institutional holders of DNLI

Denali Therapeutics top institutional holders
InstitutionShares% HeldChange
T. Rowe Price Investment Management, Inc.19.62M12.24%+21.3%
Blackrock Inc.14.33M8.94%+2.2%
BAILLIE GIFFORD & CO11.12M6.94%-7.0%
Temasek Holdings (Private) Ltd7.01M4.38%0.0%
Vanguard Portfolio Management LLC6.76M4.22%+4.3%
Vanguard Capital Management LLC6.75M4.21%+7.6%
State Street Corporation6.68M4.17%-5.2%
FMR, LLC4.53M2.83%-0.1%
Geode Capital Management, LLC4.04M2.52%+1.6%
Goldman Sachs Group Inc3.75M2.34%-9.7%

% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.

Top mutual fund and ETF holders of DNLI

Denali Therapeutics top fund holders
FundShares% Held
T. ROWE PRICE CAPITAL APPRECIATION Fd., INC.-T. Rowe Price Capital App4.97M3.10%
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund4.29M2.68%
iShares Trust-iShares Russell 2000 ETF3.81M2.38%
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund3.10M1.93%
SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF3.06M1.91%
VANGUARD WORLD FUND-Vanguard U.S. Growth Fund2.68M1.67%
SmallCap World Fund Inc2.50M1.56%
T. Rowe Price Small-Cap Stock Fund, Inc.2.33M1.45%
VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund1.78M1.11%
VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund1.73M1.08%

Frequently asked questions

Who is the largest shareholder of Denali Therapeutics?

T. Rowe Price Investment Management, Inc. is the largest institutional shareholder of DNLI, owning 12.24% of shares outstanding (19.62M shares) as of its latest 13F filing.

What percentage of Denali Therapeutics is owned by institutions?

Institutions own about 100.1% of DNLI shares and 104.9% of the public float.

How much of Denali Therapeutics do insiders own?

Insiders, such as officers and directors, own about 4.59% of DNLI shares outstanding.

Where does institutional ownership data come from?

Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.

Related